MRI Interventions Welcomes Seasoned Medical Device Executive Wendelin Maners as Its New Vice President, Marketing

IRVINE, Calif., Dec. 4, 2014 (GLOBE NEWSWIRE) -- MRI Interventions, Inc. (OTCQB:MRIC) today announces the addition of medical device veteran Wendelin Maners in the role of Vice President, Marketing, as CEO-elect Frank Grillo solidifies his management team. As Vice President, Marketing, Ms. Maners will head all marketing activities and programs, as well as develop and lead internal and external training programs for the Company.

Ms. Maners joins MRI Interventions with over two decades of global medical device experience focused on the marketing, acquisition, and licensing of medical device technologies. Prior to joining MRI Interventions, Ms. Maners served as Vice President, Emerging Technologies with CSA Medical, where she managed commercial marketing for the company's products, led market development efforts for the company's emerging applications in new market and disease segments and developed internal and external product training programs. Prior to her time with CSA Medical, Ms. Maners served for over 14 years in various roles at Boston Scientific Corporation, most recently as Vice President, Strategy and Business Development. During that time, she developed and executed acquisition strategies in the Neuromodulation and Electrophysiology markets, managed and built technology and venture capital business relationships to assemble a portfolio of investment options for supported divisions and served as a delegate Board member/observer for Boston Scientific investments, including Cyberonics, Northstar Neuroscience, Neuropace, Intelect Medical, IntraPace, Quallion and MRI Interventions. Ms. Maners is a graduate of the University of Southern California's Marshall School of Business.

"I am excited to join the MRI Interventions team and eager to build on the work that has already been done to drive the growth of the ClearPoint system as a platform for a variety of existing and new minimally invasive neurosurgical procedures," Ms. Maners stated. "ClearPoint is a unique and disruptive technology that marks a new era of real-time visualization for minimally invasive neurosurgery. I am delighted to be a part of the commercialization of a product that I believe is helping neurosurgeons offer better care to their patients."

"Wendelin possesses the skills and background we need to solidify our ClearPoint marketing strategy as we strive to best capitalize on the large and growing opportunity in the neuro market," said Frank Grillo. "She is familiar with the challenges inherent in marketing emerging medical technologies and will be a valuable asset in our commercialization of our ClearPoint platform. I am very pleased to have her on the MRI Interventions team."

About MRI Interventions, Inc.

Building on the imaging power of MRI, MRI Interventions is creating innovative platforms for performing the next generation of minimally invasive surgical procedures in the brain and heart. The company's ClearPoint® system utilizes a hospital's existing diagnostic or intraoperative MRI scanner to enable a range of minimally invasive procedures in the brain. In partnership with Siemens Healthcare, MRI Interventions is developing the ClearTrace® system to enable MRI-guided catheter ablations to treat cardiac arrhythmias. For more information, please visit

Forward-Looking Statements

Certain matters in this press release may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements often can be identified by words such as "anticipates," "believes," "could," "estimates," "expects," "intends," "may," "plans," "potential," "predicts," "projects," "should," "will," "would," or the negative of these words or other words of similar meaning. Forward-looking statements by their nature address matters that, to different degrees, are uncertain and involve risk. Uncertainties and risks may cause MRI Interventions' actual results and the timing of events to differ materially from those expressed in or implied by MRI Interventions' forward-looking statements. Information on factors that could affect MRI Interventions' actual results and the timing of events are described in our filings with the Securities and Exchange Commission, including, without limitation, MRI Interventions' Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 14, 2014. Except as required by law, MRI Interventions undertakes no obligation to publicly update or revise any forward-looking statements contained in this press release to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statements are based.


Contact Data